The only function-preserving therapy that uses electricity to destroy prostate tumors.
Previously, patients had to choose between definitive treatment options with unfavorable urological side effects.1,2 However, there’s another option: the NanoKnife System. This minimally invasive therapy precisely targets the prostate tumor with electrical pulses, destroying cells while helping to preserve sexual function and urinary continence.3
Electrical pulses destroy all living cells within the target area with no skip lesions.4,5
Increased margin expansion without negatively impacting the rates of erectile function and incontinence in men.6,7
Ability to ablate across the urethra, nerves, and urinary sphincters to ensure treatment of lesions near vital structures while preserving a patient’s quality of life.8,9
Can treat all segments of the prostate, allowing physicians to build expertise in a single technology to optimize outcomes for patients.10,11
Treatment typically takes one hour and seamlessly integrates into your practice utilizing existing imaging and biopsy skills.11,12 Procedure time may vary based on a number of factors.
Procedures can be repeated if necessary and do not interfere with more standard treatments such as surgery or radiotherapy.13
AngioDynamics does not provide medical advice, diagnosis, or treatment. The contents of this website, including disease state information, text, graphics, images, and other material (“Content”) are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition and the appropriate treatment for a particular medical condition.
Request a Sales Representative
Reimbursement Resources and C-Code Finder Lookup
For NanoKnife System document resources please visit nanoknife.com/resources.
AngioDynamics has sponsored two key FDA-approved studies, DIRECT and PRESERVE.
The PRESERVE Study is complete, with results published on the NanoKnife System for prostate tissue ablation.
A Clinical Study That Evaluates the Effects of Irreversible Electroporation (IRE) Ablation Technology on the Treatment of Patients with Stage III Pancreatic Cancer
1. Vernooij RW, Lancee M, Cleves A, Dahm P, Bangma CH, Aben KK. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev. 2020;6(6):CD006590. Published 2020 Jun 4. doi:10.1002/14651858.CD006590.pub3
2. Biddle S. The psychological impact of active surveillance in men with prostate cancer: implications for nursing care. Br J Nurs. 2021;30(10):S30-S37. doi:10.12968/bjon.2021.30.10.S30
3. Scheltema MJ, Geboers B, Blazevski A, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int. 2023;131 Suppl 4:6-13. doi:10.1111/bju.15946
4. van den Bos, W et al. “Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.” The Journal of urology vol. 196,2 (2016): 552-9. doi:10.1016/j.juro.2016.02.2977
5. Fainberg, Jonathan et al. “Targeted Ablation Using Ultrasound-Guided Irreversible Electroporation of Index Tumors (TARGET Study): Prospective Development Study Evaluating Safety, Patient-Reported Outcomes, and Oncologic Efficacy.” Urology practice, 101097UPJ0000000000000666. 17 Jul. 2024, doi:10.1097/UPJ.0000000000000666
6. Blazevski A, Scheltema MJ, Yuen B, et al. Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: A biopsy-monitored prospective cohort. European Urology Oncology. 2020;3(3):283-290. doi:10.1016/j.euo.2019.04.008
7. de la Rosette, Jean et al. “A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.” The Journal of urology vol. 209,2 (2023): 347-353. doi:10.1097/JU.0000000000003051
8. Onik, Gary, et al. “Irreversible electroporation: Implications for prostate ablation.” Technology in Cancer Research & Treatment , vol. 6, no. 4, Aug. 2007, pp. 295–300, https://doi.org/10.1177/153303460700600405.
9. Blazevski, Alexandar, et al. “Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).” World Journal of Urology, vol. 39, no. 4, 2 June 2020, pp. 1107–1114, https://doi.org/10.1007/s00345-020-03275-z.
10. Scheltema, Matthijs J et al. “Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments.” Diagnostic and interventional radiology (Ankara, Turkey) vol. 24,5 (2018): 268-275. doi:10.5152/dir.2018.17374
11. Pivotal study of the NanoKnife system for the ablation of prostate tissue. ClinicalTrials.gov website. Accessed June 28, 2024. https://clinicaltrials.gov/study/NCT04972097
12. Cussenot O and Stricker P. Irreversible Electroporation for Patients with Localised Prostate Cancer: Expert Opinion on this Versatile Therapeutic Approach. EMJ Urol. 2021;9(1):56-62.
13. Van Riel LAMJG, Geboers B, Kabaktepe E, et al. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int. 2022;130(5):611-618. doi:10.1111/bju.15759
NanoKnife and the NanoKnife logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary.
